## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1	Address of Reporting		E	Issuer Name <b>and</b> Tick NZON PHARI NZN ]	-	•		tionship of Reporting Person(s) to Issuer all applicable) Director 10% Owner					
(Last) (First) (Middle) C/O ENZON PHARMACEUTICALS, INC.				Date of Earliest Trans	action (Month/	Day/Year)	X	Officer (give title below) Executive V.F	below	,			
685 ROUTE 202/206 (Street) BRIDGEWATER NJ 08807				lf Amendment, Date o	of Original Filec	l (Month/Day/Year)	6. Indiv Line) X	,					
(City)	(State)	(Zip)											
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
1. Title of Security (Instr. 3) 2. Transact				2A. Deemed	3. Transaction	4. Securities Acquired	• •	5. Amount of	6. Ownership	7. Nature			

	Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year)	Transaction Code (Instr. 8)		Disposed Of (D) (Inst and 5)		r. 3, 4	Securities Beneficially Owned Following	Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)	(1150.4)	(Instr. 4)
Common Stock <sup>(1)</sup>	06/14/2004		Α		27,500(2)	Α	\$ <mark>0</mark>	35,330	D	

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

			(0.9., )	<i>Julo</i> , 00		want	unto	, opuono,	oonvera		annaooj				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Transaction of Code (Instr. Der 8) Sec (A) Dis of ( (Ins		5. Num of Derivat Securit Acquir (A) or Dispos of (D) (Instr. 3 and 5)	tive ties red sed 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Employee Stock Option (Right to Buy) <sup>(3)</sup>	\$12.27	06/14/2004		A		25,000		(4)	06/14/2014	Common Stock	25,000	\$0	25,000	D	

Explanation of Responses:

1. Restricted stock granted by Enzon Pharmaceuticals, Inc. ("Enzon") pursuant to Enzon's 2001 Incentive Stock Plan and qualified under Rule 16b-3(d).

2. Of the 27,500 shares granted, 7,500 will vest on June 14, 2007, 7,500 will vest on June 14, 2008 and the remaining 12,500 will vest on June 14, 2009.

3. Employee stock option granted by Enzon pursuant to Enzon's 2001 Incentive Stock Plan and qualified under Rule 16b-3(d).

4. The option vests in four equal annual installments beginning on June 14, 2005.

/s/ Kenneth J. Zuerblis

\*\* Signature of Reporting Person Date

06/15/2004

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.